Skip to content 
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. more
| Time Frame | GRCE | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 10.03% | 0.72% | -1.31% |
| 1-Month Return | 10.64% | 1.27% | 0.78% |
| 3-Month Return | 25% | 3.13% | 3.46% |
| 6-Month Return | 22.29% | 15.81% | 6.19% |
| 1-Year Return | 15.5% | 8.89% | 11.68% |
| 3-Year Return | 4.5% | 20.79% | 71.21% |
| 5-Year Return | -90.96% | 35.89% | 74.81% |
| 10-Year Return | -94.62% | 138.44% | 256.59% |
| Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 196.00K | - | - | - | - | [{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true}] |
| Cost of Revenue | 76.00K | - | 124.00K | 11.00K | 7.00K | [{"date":"2021-03-31","value":61.29,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":8.87,"profit":true},{"date":"2025-03-31","value":5.65,"profit":true}] |
| Gross Profit | 120.00K | - | (124.00K) | (11.00K) | (7.00K) | [{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":-103.33,"profit":false},{"date":"2024-03-31","value":-9.17,"profit":false},{"date":"2025-03-31","value":-5.83,"profit":false}] |
| Gross Margin | 61.22% | - | - | - | - | [{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true}] |
| Operating Expenses | 16.54M | 15.59M | 52.16M | 11.30M | 16.68M | [{"date":"2021-03-31","value":31.71,"profit":true},{"date":"2022-03-31","value":29.89,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":21.67,"profit":true},{"date":"2025-03-31","value":31.98,"profit":true}] |
| Operating Income | (16.42M) | (15.59M) | (52.16M) | (11.31M) | (16.68M) | [{"date":"2021-03-31","value":-1641900000,"profit":false},{"date":"2022-03-31","value":-1558900000,"profit":false},{"date":"2023-03-31","value":-5215500000,"profit":false},{"date":"2024-03-31","value":-1131200000,"profit":false},{"date":"2025-03-31","value":-1667900000,"profit":false}] |
| Total Non-Operating Income/Expense | (3.42M) | 5.20M | 430.00K | (2.41M) | 4.62M | [{"date":"2021-03-31","value":-65.7,"profit":false},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":8.27,"profit":true},{"date":"2024-03-31","value":-46.3,"profit":false},{"date":"2025-03-31","value":88.92,"profit":true}] |
| Pre-Tax Income | (19.68M) | (10.47M) | (51.97M) | (14.63M) | (12.77M) | [{"date":"2021-03-31","value":-1967800000,"profit":false},{"date":"2022-03-31","value":-1046700000,"profit":false},{"date":"2023-03-31","value":-5197100000,"profit":false},{"date":"2024-03-31","value":-1463000000,"profit":false},{"date":"2025-03-31","value":-1276700000,"profit":false}] |
| Income Taxes | - | (648.00K) | (9.54M) | (1.78M) | (3.20M) | [{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":-64800000,"profit":false},{"date":"2023-03-31","value":-954200000,"profit":false},{"date":"2024-03-31","value":-177700000,"profit":false},{"date":"2025-03-31","value":-319900000,"profit":false}] |
| Income After Taxes | - | (9.82M) | (42.43M) | (12.85M) | (9.57M) | [{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":-981900000,"profit":false},{"date":"2023-03-31","value":-4242900000,"profit":false},{"date":"2024-03-31","value":-1285300000,"profit":false},{"date":"2025-03-31","value":-956800000,"profit":false}] |
| Income From Continuous Operations | (19.68M) | (9.82M) | (42.43M) | (12.85M) | (9.57M) | [{"date":"2021-03-31","value":-1967800000,"profit":false},{"date":"2022-03-31","value":-981900000,"profit":false},{"date":"2023-03-31","value":-4242900000,"profit":false},{"date":"2024-03-31","value":-1285300000,"profit":false},{"date":"2025-03-31","value":-956800000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true}] |
| Net Income | (19.68M) | (9.82M) | (42.43M) | (12.85M) | (9.57M) | [{"date":"2021-03-31","value":-1967800000,"profit":false},{"date":"2022-03-31","value":-981900000,"profit":false},{"date":"2023-03-31","value":-4242900000,"profit":false},{"date":"2024-03-31","value":-1285300000,"profit":false},{"date":"2025-03-31","value":-956800000,"profit":false}] |
| EPS (Diluted) | (32.77) | (1.58) | (5.71) | (1.54) | (1.12) | [{"date":"2021-03-31","value":-3276.97,"profit":false},{"date":"2022-03-31","value":-157.94,"profit":false},{"date":"2023-03-31","value":-571.1,"profit":false},{"date":"2024-03-31","value":-153.88,"profit":false},{"date":"2025-03-31","value":-112.23,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| GRCE | |
|---|---|
| Cash Ratio | 14.54 |
| Current Ratio | 14.96 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| GRCE | |
|---|---|
| ROA (LTM) | -10.84% |
| ROE (LTM) | -10.22% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| GRCE | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| GRCE | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.89 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Grace Therapeutics, Inc. (GRCE) share price today is $3.95
Yes, Indians can buy shares of Grace Therapeutics, Inc. (GRCE) on Vested. To buy
Yes, you can purchase fractional shares of Grace Therapeutics, Inc. (GRCE) via the Vested app. You can start investing in Grace Therapeutics, Inc. (GRCE) with a minimum investment of $1.
You can invest in shares of Grace Therapeutics, Inc. (GRCE) via Vested in three simple steps:
The 52-week high price of Grace Therapeutics, Inc. (GRCE) is $4.1. The 52-week low price of Grace Therapeutics, Inc. (GRCE) is $1.75.
The price-to-earnings (P/E) ratio of Grace Therapeutics, Inc. (GRCE) is
The price-to-book (P/B) ratio of Grace Therapeutics, Inc. (GRCE) is 0.89
The dividend yield of Grace Therapeutics, Inc. (GRCE) is 0.00%
The market capitalization of Grace Therapeutics, Inc. (GRCE) is $60.97M
The stock symbol (or ticker) of Grace Therapeutics, Inc. is GRCE
Consider the share price of Grace Therapeutics, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Grace Therapeutics, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Grace Therapeutics, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Grace Therapeutics, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Grace Therapeutics, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Grace Therapeutics, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
